Lapatinib Stada

Lapatinib, the active ingredient in Lapatinib Stada, is a Tyrosine kinase inhibitor presented as a tablet for Oral use. It treats HER2‑positive metastatic breast cancer and HER2‑positive advanced gastric or gastro‑oesophageal junction adenocarcinoma in adult patients.

GNH USA supplies Lapatinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Lapatinib acts on the HER2 signaling pathway, providing targeted therapy for specific cancers.

- HER2‑positive metastatic breast cancer: improves progression‑free and overall survival. - HER2‑positive advanced gastric cancer: delays disease progression and extends survival. - HER2‑positive gastro‑oesophageal junction adenocarcinoma: contributes to tumor control in combination regimens.

Lapatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea: frequent loose stools. - Rash: skin redness or acne‑like eruptions. - Nausea: feeling of sickness, sometimes with vomiting. - Fatigue: persistent tiredness. - Stomatitis: inflammation of the mouth lining. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Interstitial lung disease: breathing difficulties and cough. - Severe hepatic failure: jaundice, abdominal pain, elevated bilirubin. - Cardiac dysfunction: reduced left‑ventricular ejection fraction. - Stevens‑Johnson syndrome: severe skin blistering. - Severe skin reactions: toxic epidermal necrolysis. - Hemorrhagic events: unusual bleeding or bruising.

When using Lapatinib, clinicians should observe several safety measures.

- Cardiac monitoring: assess left‑ventricular function before and during therapy. - Liver function tests: check transaminases and bilirubin regularly. - Dermatologic assessment: watch for severe rash or skin reactions. - Pregnancy avoidance: drug is contraindicated; ensure effective contraception. - Dose adjustment: consider hepatic impairment when determining dose. - Store below 25°C: keep in the original packaging, protect from moisture and direct light.

Lapatinib can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Lapatinib exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels. - Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Digoxin: potential increase in serum concentration. - Other HER2‑targeted agents (e.g., trastuzumab): monitor for additive cardiac toxicity.